Geographic atrophy (GA) means irreversible central vision loss. But a new gene therapy, OCU410, just started Phase 3. Phase 2 data showed it reduced GA lesion growth by 31%, and for 20% of patients, progression halted. This is big for preserving sight.
Ocugen Doses First Patient in Phase 3 Trial for Geographic Atrophy Gene Therapy OCU410 After FDA RMA
Ocugen has initiated its global Phase 3 registrational trial, ArMaDa3, for OCU410, a one-time subretinal modifier gene therapy designed to treat geographic atrophy (GA) secondary to dry age-related ma
www.stocktitan.net
September 6, 2026 at 2:05 AM
Geographic atrophy (GA) means irreversible central vision loss. But a new gene therapy, OCU410, just started Phase 3. Phase 2 data showed it reduced GA lesion growth by 31%, and for 20% of patients, progression halted. This is big for preserving sight.
Ocugen has dosed the first patient in Phase 3 of OCU410 for geographic atrophy, with BLA filing targeted for 2028. The trial carries FDA RMAT designation.
Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD
Ocugen has initiated its Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy, backed by FDA RMAT designation and a BLA filing targeted for 2028.
biotech.disruptsmedia.com
September 14, 2026 at 4:00 PM
Ocugen has dosed the first patient in Phase 3 of OCU410 for geographic atrophy, with BLA filing targeted for 2028. The trial carries FDA RMAT designation.
Ocugen (#$OCGN) doses its first patient in ArMaDa3, a global Phase 3 trial of OCU410 gene therapy for geographic atrophy. FDA-aligned path targets a 2028 BLA filing. Phase 2 showed a 31% reduction in lesion growth; Phase 3 results aren't guaranteed to match.
prismmarketview.com/ocugen-launc...
prismmarketview.com/ocugen-launc...
Ocugen Launches Pivotal Gene Therapy Trial for Vision-Threatening Geographic Atrophy
Key Points Ocugen has dosed the first patient in ArMaDa3, its global Phase 3 registrational trial of OCU410 for geographic atrophy caused by dry age-relate
prismmarketview.com
September 1, 2026 at 8:22 PM
Ocugen (#$OCGN) doses its first patient in ArMaDa3, a global Phase 3 trial of OCU410 gene therapy for geographic atrophy. FDA-aligned path targets a 2028 BLA filing. Phase 2 showed a 31% reduction in lesion growth; Phase 3 results aren't guaranteed to match.
prismmarketview.com/ocugen-launc...
prismmarketview.com/ocugen-launc...
2/2🧵.
Gracias a la Intendencia de Mar del Plata y a la Armada🇦🇷 por su apoyo y hospitalidad.
Gracias a la Intendencia de Mar del Plata y a la Armada🇦🇷 por su apoyo y hospitalidad.
December 14, 2024 at 4:57 PM
2/2🧵.
Gracias a la Intendencia de Mar del Plata y a la Armada🇦🇷 por su apoyo y hospitalidad.
Gracias a la Intendencia de Mar del Plata y a la Armada🇦🇷 por su apoyo y hospitalidad.
February 18, 2025 at 10:10 PM